Drugs / CLE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01130493 | May 2010 → Jan 2012 | Parkinson disease | Impax Laboratories, LLC | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01130493 ↗ |